A prospective, randomized trial of two antibiotic regimens in the treatment of peritonitis in CAPD patients: teicoplanin plus tobramycin versus cephalothin plus tobramycin

The Journal of Antimicrobial Chemotherapy
A LupoG Maschio

Abstract

A multicentre, comparative, randomized study was performed to compare the efficacy and tolerability of two antibiotic regimens in the treatment of peritonitis in continuous ambulatory peritoneal dialysis (CAPD) patients: teicoplanin plus tobramycin versus cephalothin plus tobramycin. After informed consent had been obtained, 68 patients were randomized prospectively to receive either teicoplanin plus tobramycin or cephalothin plus tobramycin. Patients were followed throughout the study and for up to 4 weeks after the end of treatment, when clinical and microbiological parameters were assessed again. The incidence of clinical failure was 4.6 times higher in the cephalothin plus tobramycin group than in the teicoplanin plus tobramycin group (7/28 versus 2/37; P < 0.05). There was no significant difference in bacterial eradication between the two groups. Local and systemic tolerability were good for both regimens. The study shows that teicoplanin plus tobramycin is more effective than cephalothin plus tobramycin and might become a 'first-line' treatment for peritonitis in CAPD patients.

Citations

May 30, 2012·Peritoneal Dialysis International : Journal of the International Society for Peritoneal Dialysis·V LiakopoulosN Dombros
Nov 27, 2007·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Kathryn J WigginsGiovanni F M Strippoli
May 5, 2010·Therapeutic Apheresis and Dialysis : Official Peer-reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy·Chin-Chan LeeMai-Szu Wu
Apr 29, 2014·The Cochrane Database of Systematic Reviews·Angela E BallingerGiovanni F M Strippoli
Jul 11, 2018·Peritoneal Dialysis International : Journal of the International Society for Peritoneal Dialysis·A Mancini, L Todd
Jun 11, 2016·Peritoneal Dialysis International : Journal of the International Society for Peritoneal Dialysis·Philip Kam-Tao LiDavid W Johnson
Dec 29, 2000·Seminars in Dialysis·T A GolperE M D'Agata

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.